Corpus Intelligence IC Memo — VALLEY CHILDRENS HOSPITAL 2026-04-26 06:39 UTC
IC Memo — VALLEY CHILDRENS HOSPITAL
Investment Committee Memorandum | CA | 358 beds | Grade B | EBITDA uplift $74.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

VALLEY CHILDRENS HOSPITAL

CCN 053300 | MADERA, CA | 358 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

VALLEY CHILDRENS HOSPITAL is a 358-bed safety-net/medicaid heavy in MADERA, CA with $1.01B in net patient revenue and a 25.0% operating margin. The hospital serves a payer mix of 0.1% Medicare, 48.8% Medicaid, and 51.1% commercial.

Thesis: Platform Growth. Our ML models identify $74.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 25.0% to 32.4% (+736bps).

Net Revenue HCRIS$1.01B
Current EBITDA COMPUTED$252.9M
Operating Margin COMPUTED25.0%
Occupancy HCRIS50.5%
Revenue / Bed COMPUTED$2.8M
Net-to-Gross HCRIS49.3%
Distress Probability ML58.6%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
154
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 25.0% places it above the state median. Among 154 size-comparable peers (179-716 beds), the median margin is -4.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (179-716), prioritizing same-state peers. 154 hospitals in the comp set.

HospitalStateBedsRevenueMargin
VALLEY CHILDRENS HOSPITAL (Target)CA358$1.01B25.0%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $74.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$21.2M+210bp18mo
Cost to Collect4.5%2.5%$20.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$20.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$12.3M+122bp9mo
Clean Claim Rate88.0%96.0%$646K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$21.2M
Cost to Collect
$20.2M
Denial Rate Reduction
$20.0M
A/R Days Reduction
$12.3M
Clean Claim Rate
$646K
Total EBITDA Uplift$74.4M
Current EBITDA$252.9M
+ RCM Uplift+$74.4M
Pro Forma EBITDA$327.2M
Current Margin25.0%
Pro Forma Margin32.4%
WC Released (1x)$38.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$389.1M$2.41B6.20x44.0%
Base (11x exit)10.0x11.0x$389.1M$2.78B7.14x48.2%
Bull Case9.0x11.0x$350.1M$3.15B9.00x55.2%
Bull (12x exit)9.0x12.0x$350.1M$3.54B10.11x58.8%
Bear Case11.0x10.0x$428.0M$1.91B4.47x34.9%
Bear (11x exit)11.0x11.0x$428.0M$2.24B5.24x39.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (48.8%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 58.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 154 hospitals with 179-716 beds
  • Same-state prioritization (n=155)
  • Comp margins: P25=-15.9% / P50=-4.4% / P75=3.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.